https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41489
https://www.ncbi.nlm.nih.gov/pubmed/32798283?dopt=Abstract
TITLE:
Nuclease Therapy Improves Severe Fatigue in Primary Sjögren’s Syndrome: A Randomized Clinical Trial.
DESCRIPTION:
Nuclease Therapy Improves Severe Fatigue in Primary Sjögren’s Syndrome: A Randomized Clinical Trial.
Arthritis Rheumatol. 2020 Aug 15;:
Authors: Posada J, Valadkhan S, Burge D, Davies K, Tarn J, Casement J, Jobling K, Gallagher P, Wilson D, Barone F, Fisher BA, Ng WF
Abstract
OBJECTIVE: To assess the safety and efficacy of RSLV-132, an RNase Fc fusion protein in a phase II randomized, double-blind, placebo-controlled clinical trial in patients with primary Sjögren’s syndrome (pSS).
METHODS: Thirty patients were randomized to receive intravenous RSLV-132 or placebo, weekly for two weeks then every two weeks for twelve weeks. Eight subjects received placebo and twenty received RSLV-132, 10 mg/kg. Clinical efficacy measures included the European League Against Rheumatism (EULAR) Sjögren’s syndrome disease activity index (ESSDAI), EULAR Sjögren’s syndrome patient reported index (ESSPRI), FACIT fatigue (FACIT-F), and profile of fatigue (ProF), and the digit symbol substitution test (DSST).
RESULTS: Patients randomized to RSLV-132, but not placebo, experienced clinically meaningful improvements in ESSPRI, FACIT-F, ProF, and DSST. This improvement was correlated with increased expression of selected interferon-inducible genes.
CONCLUSION: Administration of RSLV-132 improved severe fatigue in pSS patients as determined by four independent measures of fatigue.
PMID: 32798283 [PubMed – as supplied by publisher]
PMID:
PubMed:32798283
DATE FOUND:
08/17/20 06:03AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32798283?dopt=Abstract
